SERPASIL
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Aug 1954
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SERPASIL is an injectable small-molecule product approved in 1954 by Novartis. Specific indication and mechanism of action data are not available in current records. This legacy product represents an older therapeutic category with established clinical use.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100) and minimal linked job openings, indicating a mature, stable team with limited growth headroom.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
SERPASIL currently has zero linked job openings, reflecting its mature lifecycle status and approaching LOE. Career moves to this product are typically limited to defensive commercial roles focused on market maintenance and generic transition planning.
Brand ManagerField Sales Representative
Worked on SERPASIL at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.